Background:
The DRUCK-Surv study collects bio-behavioural data from people who inject drugs (PWID), who are disproportionately affected by these infections. Results are used to monitor Germany’s progress towards the WHO’s 2030 targets for eliminating HIV and viral hepatitis B and C (HBV, HCV). We present preliminary laboratory findings.
Methods:
Between February and July 2025, 71 low-threshold drug- and 22 medical facilities, including opioid agonist treatment centres, are collecting dried blood spots or venous blood samples from 3,000 PWID. Eligible participants include individuals aged 16 or older who have recently (last 12 months) or ever injected drugs. Participants complete a questionnaire on sociodemographic characteristics, behavioural factors, testing and treatment history. All participants receive a €15 voucher and can retrieve their test results from the testing site. Blood samples are tested for HBV (anti-HBc, anti-HBs, HBs-Ag), HCV (anti-HCV, HCV-RNA), and HIV (anti-HIV + confirmation). Test results are presented stratified by injecting drug use history (recent | ever).
Results:
As of 23.04.2025, 1.167 samples (38.9% of target) had been submitted for analysis from 64 facilities.
Prevalences among people who have recently injected drugs vs. those who ever injected drugs, were: anti-HCV 81.3% (125/667) vs. 76.2% (301/395), HCV RNA 32.4% (223/688) vs. 11.7% (47/401), confirmed HIV 5.3% (35/665) vs. 5.3% (21/396), HBsAg 2.8% (18/653) vs. 1.3% (5/392) and AntiHBc 18.3% (149/815) vs. 24.0% (125/521). Questionnaire data analysis is pending.
Conclusion:
Among recent injectors, prevalence of viraemic HCV and HBV infection remain alarmingly high, indicating gaps in access to treatment and vaccination. Many participants had a prior HBV and HCV exposure. In both strata, HIV prevalence was high, similar to previous studies. Questionnaire data will show potential gaps in access to HIV treatment. Sociodemographic data is needed for subgroup analyses to refine recommendations and guide targeted interventions. |